Cognition/Mood

Aniracetam

Synthetic racetam compound studied for cognitive symptoms in older adults with vascular impairment; benefits in healthy people are unproven.

Aniracetam

Aniracetam

38
score
C
evidence
Caution
risk
Quick Take

Skip for healthy cognitive enhancement — evidence is limited to small studies in older clinical populations.

Aniracetam is a synthetic nootropic in the racetam family developed in the 1970s. It is approved for cognitive impairment in some countries, but not in the United States. Small clinical trials in elderly patients with cerebrovascular disorders suggest modest improvements in cognitive ratings and behavior. Animal studies indicate it modulates AMPA receptors and cholinergic signaling, but human mechanistic data are limited. Healthy adults seeking memory or focus enhancement have little controlled human evidence to support meaningful effects.

Proven Benefits

01
May improve cognition
02
May reduce anxiety
03
May improve post-stroke cognition
04
May improve mood

Protocol

Amount
750-1500 mg
Frequency
Twice daily, morning and early afternoon
When
With meals containing fat to improve absorption; lipophilic compound.

Onset Time

2-4 weeks for subjective effects in trials; acute benefits unproven.

Who Should Consider

Older adults with vascular cognitive impairment
People with post-stroke cognitive symptoms

How It Works

Aniracetam acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic neurotransmission. It also appears to facilitate acetylcholine release in animal models, with downstream effects on dopamine and serotonin pathways. Human neurochemical data confirming these mechanisms are sparse.

Updated Invalid Date